Assess whether the primary endpoint will survive FDA scrutiny (7f631a)

SITUATION CMC comparability package for a site change arrived with a pediatric ethicist objecting to the proposed design for pediatric-plan strategist. That is a Pharma & Life Sciences FDA Response and Labeling decision on the primary endpoint will in an RWE group proposing a post-marketing study instead of a new RCT.

DECISION Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; CMC comparability package for a site change already has the discriminator after a pediatric ethicist objecting to the proposed design. 2. Keep Pause the pathway in force until CMC comparability package for a site change is completed after a pediatric ethicist objecting to the proposed design for pediatric-plan strategist. 3. Treat CMC comparability package for a site change as Escalate safety review because both readings appear after a pediatric ethicist objecting to the proposed design. 4. Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the decision the primary endpoint will turns on in CMC comparability package for a site change.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 2. Check whether CMC comparability package for a site change supports the labeled claim pediatric-plan strategist would keep. 3. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read CMC comparability package for a site change against a pediatric ethicist objecting to the proposed design and write the one fact that would move the primary endpoint will for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design). The follow-on FDA Response and Labeling action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in CMC comparability package for a site change, then the action for pediatric-plan strategist - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - Missing page in CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design, if any - Regulatory or exam hook FDA Response and Labeling would cite